Uveal melanoma survival in Sweden from 1960 to 1998

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 8, 2003, Pages 3282-3287

  Bergman, Louise ^a   Seregard, Stefan ^a   Nilsson, Bo ^b   Lundell, Göran ^b   Ringborg, Ulrik ^b   Ragnarsson Olding, Boel ^b  

^a ST ERIK S EYE HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CAUSE OF DEATH; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; SWEDEN; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH SURVEYS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MELANOMA; MIDDLE AGED; REGISTRIES; SURVIVAL RATE; SWEDEN; UVEAL NEOPLASMS;

EID: 0041842755     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0081     Document Type: Article

References (36)

1. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245-250.
2. Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma: a meta-analysis of studies including 1,066 patients. Acta Ophthalmol Scand. 1999;77:414-417.
3. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer. 1993;71:2299-2305.
4. Kroll S, Char DH, Quivey J, Castro J. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. Ophthalmology. 1998;105:2035-2045.
5. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol (Copenh). 1982;60:161-182.
6. Shields JA, Augsburger JJ, Donoso LA, Bernardino VB Jr, Portenar M. Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years. Am J Ophthalmol. 1985;100:666-668.
7. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-389; discussion 390.
8. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-336.
9. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res. 1999;9:575-581.
10. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840-845.
11. De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment: a literature review. Bull Soc Belge Ophtalmol. 2002;286:59-63.
12. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:2366-2372.
13. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97:465-475.
14. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol. 1999;237:558-567.
15. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology. 1990;97:769-777.
16. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001; 119:969-982.
17. Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol. 1998;125:81-89.
18. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, II initial mortality findings, COMS report No. 10. Am J Ophthalmol. 1998;125:779-796.
19. Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2002;43:2579-2583.
20. Official Statistics of Sweden. Stockholm: The National Swedish Central Bureau of Statistics. Annual Publications; 1960-1998.
21. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Prog Biomed. 1985;19:197-207.
22. Livslängdstabeller (Life tables) 1960-1998: Stockholm: The National Swedish Central Bureau of Statistics. Official Statistics of Sweden. Annual Publications. 1960-1998.
23. Hakulinen T, Tenkanen L. Regression analysis of relative survival rates. Appl Stat. 1987;36:309-317.
24. Francis B, Green M, Payne CD, eds. The GLIM System. Release 4: Generalized Linear Interactive Modelling System Manual. Oxford, UK: Clarendon Press; 1993.
25. McLean IW, Gamel JW. Cause-specific versus all-cause survival. Ophthalmology. 1998;105:1989-1990.
26. Kelson M, Farebrother M. The effect of inaccuracies in death certification and coding practices in the European Economic Community (EEC) on international cancer mortality statistics. Int J Epidemiol. 1987;16:411-414.
27. Hoel D, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends. J Natl Cancer Inst. 1993;85:1063-1068.
28. Johansson LA, Westerling R. Comparing hospital discharge records with death certificates: can the differences be explained? J Epidemiol Community Health. 2002;56:301-308.
29. Percy C, Stanek E 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981;71:242-250.
30. Ederer F, Axtell L, Cutler S. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-212.
31. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107:1443-1449.
32. Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology. 2001;108:829-831.
33. Thorn M, Adami HO, Bergstrom R, Ringborg U, Krusemo UB. Trends in survival from malignant melanoma: remarkable improvement in 23 years. J Natl Cancer Inst. 1989;81:611-617.
34. Eskelin S, Kivela T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol. 2002;86:333-338.
35. Ah-Fat FG, Damato BE. Delays in the diagnosis of uveal melanoma and effect on treatment. Eye. 1998;12:781-782.
36. Lundström M, Stenevi U, Thorburn W. Gender and cataract surgery in Sweden 1992-1997: a retrospective observational study based on the Swedish National Cataract Register. Acta Ophthalmol Scand. 1999;77:204-208.